UNH Valuation Hits 36% Rebound Milestone Amid Membership Loss Concerns
UnitedHealth Group's shares fell by 3.2% on Wednesday to $387.97, but this decline is not necessarily a sign that the company's stock price has become undervalued. Despite its current price being 36.1% higher than its March 9 close, UNH remains at an expensive valuation of 19.6 times its midpoint 2026 adjusted-earnings guidance.
The company's second-quarter results provided evidence for the rebound, with revenue reaching $112.0 billion and operating earnings hitting $8.0 billion. However, medical membership fell by 1.6 million compared to the prior year period, and Optum Health saw a similar decline in value-based-care patients.
Investors should be cautious about relying on reserve releases as a growth engine, as these are not sustainable in the long term. The market needs cost control to remain effective after this support fades.